These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9239474)

  • 1. Successful separation between benign prostatic hyperplasia and prostate cancer by measurement of free and complexed PSA.
    Lilja H; Stenman UH
    Cancer Treat Res; 1996; 88():93-101. PubMed ID: 9239474
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate-specific antigen (hK3) and human prostatic glandular kallikrein (hK2) in the detection of early stage human prostate cancer.
    Wilson MJ
    J Lab Clin Med; 1998 Apr; 131(4):298-9. PubMed ID: 9579381
    [No Abstract]   [Full Text] [Related]  

  • 3. Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used?
    Lein M; Stephan C; Jung K; Schnorr D; Loening S
    Cancer Invest; 1998; 16(1):45-9. PubMed ID: 9474251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total, free and complexed PSA and hK2 for early detection of prostate cancer.
    Haese A; Khan MA; Sokoll LJ
    MLO Med Lab Obs; 2003 Jun; 35(6):14-6, 20, 22 passim; quiz 30-1. PubMed ID: 12841068
    [No Abstract]   [Full Text] [Related]  

  • 5. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF; Mensink HJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
    España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ
    J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
    Magklara A; Scorilas A; Catalona WJ; Diamandis EP
    Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prostate-specific antigen and prostatic cancer].
    Otnes B; Tveter KJ
    Tidsskr Nor Laegeforen; 1994 Mar; 114(7):829. PubMed ID: 7516585
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia.
    Tchetgen MB; Oesterling JE
    Urol Clin North Am; 1995 May; 22(2):333-44. PubMed ID: 7539179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
    Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
    Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia.
    Charrier JP; Tournel C; Michel S; Dalbon P; Jolivet M
    Electrophoresis; 1999; 20(4-5):1075-81. PubMed ID: 10344287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer.
    Zhang WM; Finne P; Leinonen J; Salo J; Stenman UH
    Urology; 2000 Aug; 56(2):267-72. PubMed ID: 10925092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance of prostate-specific antigen].
    Tveter KJ; Otnes B
    Tidsskr Nor Laegeforen; 1994 Jan; 114(2):160-2. PubMed ID: 7510073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
    Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)].
    de la Taille A; Houlgatte A; Houdelette P; Berlizot P; Ramirez J; Ricordel I
    Prog Urol; 1997 Apr; 7(2):240-5. PubMed ID: 9264766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
    Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
    Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum-to-urinary prostate-specific antigen ratio: a potential means of distinguishing benign prostatic hyperplasia from prostate cancer.
    Irani J; Millet C; Levillain P; Doré B; Begon F; Aubert J
    Eur Urol; 1996; 29(4):407-12. PubMed ID: 8791046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
    Stephan C; Jung K; Lein M; Sinha P; Schnorr D; Loening SA
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1133-47. PubMed ID: 11097220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.